ARTES successfully completed EU funded project Plurivax

ARTES Biotech­nol­o­gy explored very effec­tive in a SME con­sor­tium vac­cine devel­op­ments for vet­eri­nary appli­ca­tions.
Under the titel: “ERA-Net EuroTransBio‑8: PLURIVAX, devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions, the EU coop­er­a­tion was part of the 8th Euro­Trans­Bio call and was fund­ed in the time peri­od from June 2014 to Novem­ber 2017 by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).
For the devel­op­ment of vac­cines for human appli­ca­tions it is state of the art to use virus-like par­ti­cles (VLPs) as a vehi­cle. The use of these par­ti­cles has the advan­tage that they as such not being infec­tious but that they trans­port for­eign anti­gens in an ide­al way to the immune sys­tem. These very effec­tive and sim­ple mech­a­nism was the back­bone of the PLURIVAX project.
“As ini­tial nucle­us our pro­pri­etary VLP plat­form METAVAX® was tak­en. This plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cine can­di­dates against dif­fer­ent human relat­ing dis­eases like flu, malar­ia and HIV”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “Our expres­sion host, the methy­lotroph­ic yeast Hansenu­la poly­mor­pha, is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Com­bi­na­tion of our both plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.”
ARTES chose eight dif­fer­ent, large mol­e­c­u­lar weight anti­gens derived from four animal‑ infect­ing virus­es. The bovine viral diar­rhea virus (BVDV) as an impor­tant pathogen of cat­tle, also infect­ing sheep and pigs. The clas­si­cal swine fever virus (CSFV), which is acknowl­edged as a glob­al threat for swine and is list­ed as noti­fi­able ani­mal dis­eases by the World Orga­ni­za­tion for Ani­mal Health. The feline leukemia virus (FeLV) as a retro­virus threat­en­ing domes­tic cats and the west nile virus (WNV) which is a mos­qui­to vec­tor trans­mit­ted zoonot­ic virus of the Fla­viviri­dae fam­i­ly. WNV cir­cu­lates in birds as nat­ur­al hosts but can be trans­mit­ted to mam­mals includ­ing humans caus­ing west nile fever.
First results were released in a sci­en­tif­ic paper under the title “Estab­lish­ment of a yeast-based VLP plat­form for anti­gen pre­sen­ta­tion” (Wet­zel et al. Microb Cell Fact (2018) 17:17 )
and more infor­ma­tion could be get on‑0868‑0

Future steps are, that in close dis­cus­sions with glob­al vet­eri­nary vac­cine man­u­fac­tur­er, ARTES’ explores the com­mer­cial appli­ca­tion of the results and of the plat­form in gen­er­al.

ARTES attends Bio-Europe Spring 2018

Meet us at the Bio-Europe Spring 2018 tak­ing place in Ams­ter­dam March 12 ‑14. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES brings new vaccine advances to veterinary ‘Dragons’ Den’

ARTES will attend February’s Euro­pean Ani­mal Health Invest­ment Forum in Lon­don and will present its inno­v­a­tive tech­nolo­gies to poten­tial part­ners
This will be ARTES’ sec­ond par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event, which is seen as the ‘Drag­ons’ Den’ of vet­eri­nary med­i­cine.
ARTES Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, will use the forum to talk with inter­est­ed par­ties about lat­est devel­op­ments of the laboratory’s inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®, which received a new EU-based grant of patent last August.
Meet us at the Euro­pean Ani­mal Health Invest­ment Forum tak­ing place in Lon­don, Feb­ru­ary 20 ‑21. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES attends Biofit 2017

Meet us at the Biofit 2017 tak­ing place in Stras­bourg Novem­ber 28 ‑29. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing and we are present with our own booth (num­ber F2). Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotech­nol­o­gy GmbH today announced that it has just obtained gov­ern­men­tal approval for ‘Crédit d’Im­pôt Recherche’ (CIR) for a three-year peri­od from the French Min­istry of High­er Edu­ca­tion and Research (MESR).

The French R&D tax cred­it CIR gives French com­pa­nies the abil­i­ty to claim tax relief on 30% on all gen­er­at­ed costs out­sourced to ARTES’ R&D ser­vices.
“We are pleased to receive this accred­i­ta­tion and to be approved as valid and reli­able R&D provider from the French Min­istry”, Dr Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES. “It allows our cus­tomers in France to ben­e­fit from tax relief of their R&D expens­es com­mit­ted to us and it will help us to tie up our rela­tion­ships with our present clients in France and to install new col­lab­o­ra­tions”.

ARTES Biotech­nol­o­gy is glob­al­ly active as R&D com­pa­ny spe­cial­ized in devel­op­ing bio­phar­ma­ceu­ti­cal and vac­cine pro­duc­tion process­es.
The com­pa­ny oper­ates world­wide from its 850 m² S1 facil­i­ties in Lan­gen­feld, from where it also offers cell line engi­neer­ing based on yeast (Hansenu­la poly­mor­pha) and bac­te­r­i­al (E. coli and Bacil­lus) expres­sion plat­forms, lab scale up- and down­stream process devel­op­ment, sup­ply of non-GMP bulk mate­r­i­al (API) for activ­i­ty and tox­i­c­i­ty tests and tech­nol­o­gy trans­fer to cGMP facil­i­ties and scale-up sup­port.

ARTES was part of a successful international consortium

EU Research Project Nano3Bio sums up:
Promis­ing achieve­ments for win­ning future raw mate­ri­als

Since fos­sil raw mate­ri­als are rapid­ly run­ning out, their sub­sti­tu­tion by renew­able resources is becom­ing increas­ing­ly impor­tant. In this process, the bio­log­i­cal pro­duc­tion of raw mate­ri­als will have to play a lead­ing role. The inter­na­tion­al project Nano3Bio, includ­ing ARTES Biotech­nol­o­gy has con­tributed to mas­ter this chal­lenge. Nano3Bio’s main goal was the biotech­no­log­i­cal pro­duc­tion of so-called chi­tosans, which can be used as raw mate­ri­als for med­i­cine, agri­cul­ture, cos­met­ics and oth­er appli­ca­tion fields. The Euro­pean Com­mis­sion sup­port­ed the research project with almost nine mil­lion Euros over the past four years. Recent­ly, the con­sor­tium held its final con­fer­ence ‘The Future of Chi­tosans’ in Hyder­abad, India.
“We’re proud of Nano3Bio’s out­comes. In impor­tant fields, the con­sor­tium achieved or pre­pared break­throughs from basic research to biotech­no­log­i­cal appli­ca­tions”, says Pro­fes­sor Dr. Bruno Moer­schbach­er, biol­o­gist at the Uni­ver­si­ty of Mün­ster and coor­di­na­tor of the project.

More about Nano3Bio and on the future of chi­tosans:

ARTES received next grant of patent for METAVAX®

ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-par­ti­cle (VLP) tech­nol­o­gy plat­form METAVAX®.

The new patent inte­grates exact­ly in our exist­ing patent port­fo­lio and will fur­ther strength­en our tech­nol­o­gy offer”, said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES. “In com­bi­na­tion with our pro­pri­etary yeast expres­sion tech­nol­o­gy our anti­gen pre­sen­ta­tion plat­form METAVAX® is an excel­lent and unique tool for the devel­op­ment of effec­tive, safe and afford­able vac­cines.”

Cur­rent­ly, the plat­form METAVAX® is used in sev­er­al clients’ projects as well as in sev­er­al in-house research projects. With­in the “Pluri­vax” project, fund­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) as part of the 8th Euro­Trans­Bio call, ARTES enhances its VLP based vac­cine plat­form METAVAX® and devel­ops process­es espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions.

Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. With this new patent, we have addi­tion­al rein­force­ment to our exist­ing patent estate,” said Dr. Melanie Pio­ntek.


A con­sor­tium of 5 com­pa­nies and the Fraun­hofer-Insti­tut für Lasertech­nik ILT, aim to devel­op under the name of WAVESCATTER („Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik“) a new kind of scat­tered light sen­sor for pre­cise inline par­ti­cle ana­lyt­ic.

The project will be fund­ed for a three year peri­od by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) in the pro­gram Dig­i­tale Optik«.

Part­ner of the con­sor­tium are:

  • Hell­ma GmbH & Co. KG, Müll­heim (Kon­sor­tialführer)
  • ABS Gesellschaft für Automa­tisierung, Bild­ver­ar­beitung und Soft­ware mbH, Jena
  • ARTES Biotech­nol­o­gy GmbH, Lan­gen­feld (Rhein­land)
  • Light­Fab GmbH, Aachen
  • HiTec Zang GmbH, Her­zo­gen­rath.


PR in Ger­man lan­guage:

Mit Photonen im Trüben messen

Vielfältige chemis­che und biotech­nol­o­gis­che Prozesse sind mit dem Entste­hen, dem Wach­s­tum oder der Verän­derung von Par­tikeln ver­bun­den. Eine detail­lierte Beobach­tung von Par­tikel­größe und Par­tike­lan­zahl im laufend­en Prozess ohne zeit- und arbeit­saufwändi­ge Probe­nent­nahme soll die Überwachung und Steuerung solch­er Prozesse in Echtzeit zukün­ftig vere­in­fachen oder über­haupt erst ermöglichen. Im Pro­jekt »WAVESCATTER« haben sich dazu vier Unternehmen und das Fraun­hofer-Insti­tut für Lasertech­nik ILT zusam­mengeschlossen. Ziel ist die Entwick­lung ein­er winke­lau­flösenden Wellen­leit­er-Streulicht­sonde für die präzise Inline-Par­tike­l­an­a­lytik.

Wirk­stoffe für Medika­mente wer­den heute zum großen Teil durch spezielle Mikroor­gan­is­men in Biore­ak­toren pro­duziert, wo die Wach­s­tum­sprozesse von beson­der­er Bedeu­tung sind. Die Mikrobenkul­tur wird zusam­men mit ein­er geeigneten Nährlö­sung in den Biore­ak­tor gebracht, ver­mehrt sich dort und pro­duziert die gewün­schte Sub­stanz wie z.B. Insulin, den Leben­sret­ter für Dia­betik­er. Die Mikrobenkul­tur im Biore­ak­tor darf auf keinen Fall mit anderen Mikroor­gan­is­men verun­reinigt wer­den. Dies gelingt am besten, wenn der Reak­tor her­metisch abgeschlossen wird, bis der Pro­duk­tion­sprozess been­det ist. Die Her­aus­forderung liegt in der ständi­gen Überwachung des Prozess­es für einen opti­malen Ablauf, um beispiel­sweise die Nährstof­fzu­gabe an das Wach­s­tumsver­hal­ten der Mikroor­gan­is­men anzu­passen. Eine regelmäßige Proben­nahme mit nach­fol­gen­der Offline-Analyse der Mikrobenkul­tur ist nicht nur arbeits- und zeit­in­ten­siv, son­dern stellt auch eine mögliche Kon­t­a­m­i­na­tion­squelle für den Biore­ak­tor dar. Bis­lang wer­den Proben aus dem Reak­tor ent­nom­men und verdün­nt, um z.B. die Größen­verteilung und Anzahldichte der Mikroor­gan­is­men messen zu kön­nen. Mit der im WAVESCATTER Pro­jekt anvisierten Tech­nolo­gie wird eine inline-fähige Par­tike­l­an­a­lytik entwick­elt, die ohne Proben­verdün­nung auch in optisch dicht­en Lösun­gen Par­tikel­größen zwis­chen weni­gen 10 nm und mehreren µm in Echtzeit bes­timm­bar macht. Dadurch wer­den völ­lig neue Möglichkeit­en zur rück­gekop­pel­ten Überwachung und Steuerung von chemis­chen und biotech­nol­o­gis­chen Pro­duk­tion­sprozessen ermöglicht. Eine Kon­t­a­m­i­na­tion des Fer­menters durch uner­wün­schte Frem­dor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Qual­itätssicherung und Prozes­saus­beute kön­nen so verbessert wer­den. Damit die Probe­nent­nahme aus einem Biore­ak­tor nicht mehr notwendig ist, hat sich das Kon­sor­tium in diesem Ver­bund­pro­jekt zusam­menge­fun­den. Ziel ist die Entwick­lung ein­er optis­chen Tauch­sonde, welch­er durch eine winke­laufgelöste Streulichtmes­sung die Größen­verteilung von Par­tikeln z.B. in Biofer­mentern bes­tim­men kann. Die Licht­führung in der Sonde erfol­gt mit Hil­fe von Wellen­leit­ern, die Licht­de­tek­tion mit ein­er CCD / CMOS Zeile. Aus dem winke­laufgelösten Streulichtsig­nal kön­nen über die Par­tikel­größen­verteilung Infor­ma­tio­nen zu Zell­größe und Teilchen­zahldichte im Inneren des Biore­ak­tors gewon­nen und zur Prozesss­teuerung ver­wen­det wer­den. Eine Fremdbe­siedelung durch uner­wün­schte Mikroor­gan­is­men kann frühzeit­ig erkan­nt wer­den. Per­spek­tivisch ist auch die Ermit­tlung von wichti­gen zell­bi­ol­o­gis­chen Para­me­tern möglich (Lebend- / Totzel­lun­ter­schei­dung, Erken­nung von intrazel­lulären Inklu­sion­skör­pern).

Nach erfol­gre­ichem Pro­jek­tab­schluss ste­ht der Prozes­s­an­a­lytik in den Bere­ichen Arzneimit­tel­her­stel­lung und Lebens­mit­tel­pro­duk­tion ein neues Werkzeug zur Ver­fü­gung, mit dem Prozess­pa­ra­me­ter ein­fach­er, flex­i­bler und umfassender in Echtzeit und ohne Probe­nahme erfasst wer­den kön­nen. Weit­ere Ein­satzge­bi­ete kön­nen chemis­che Poly­meri­sa­tion­sreak­tio­nen, Kristalli­sa­tio­nen oder Dis­per­sion­sprozesse sein.

Das Pro­jekt „Winke­lau­flösende Wellen­leit­er-Streulicht­sonde für die Inline-Prozes­s­an­a­lytik — WAVESCATTER“ wird vom BMBF im Rah­men der Pho­tonik Forschung Deutsch­land, Förderini­tia­tive »Dig­i­tale Optik«, unter dem Förderkennze­ichen 13N14176 mit ins­ge­samt 2,1 Mio € gefördert.

BIO International Convention 2017

Meet us at the BIO Inter­na­tion­al Con­ven­tion tak­ing place in San Diego, CA, USA  June 19 ‑22.

Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem.

We look for­ward to meet­ing you!

15 Years ARTES Biotechnology

Toady, ARTES has 15 year anniver­sary. In 2002 at May 10th Michael Pio­ntek found­ed ARTES as R&D com­pa­ny, spe­cial­ized in devel­op­ing yeast cell lines for recom­bi­nant pro­tein pro­duc­tion. In 15 years ARTES has posi­tioned itself as val­ued part­ner for the phar­ma­ceu­ti­cal and life sci­ence indus­try and it is now spe­cial­ized in devel­op­ing whole biotech­nol­o­gy pro­duc­tion process­es.